CVS Health reported its fourth quarter and full-year 2024 earnings, beating Wall Street’s expectations. The company’s stock rose 15% for the day. Full-year revenue reached $372.8 billion, while fourth-quarter revenue was $97.7 billion, exceeding estimates of $96.8 billion.
The healthcare benefits segment saw a decline due to ongoing Medicare and Medicaid headwinds, but the retail pharmaceutical business and healthcare services segment showed growth. CVS’s medical loss ratio (MLR) improved slightly to 92.5%, below the Affordable Care Act’s mandate of 80-85% for premium dollars.
Despite a tumultuous year with a new CEO, David Joyner, taking over, CVS reported adjusted earnings per share of $5.75-$6 for 2025. However, annual revenue guidance was not provided. The company expressed confidence in growth areas like the Pharmacy and Consumer Wellness segment while addressing industry-wide challenges.
CEO David Joyner stated that despite headwinds, the company has seen growth in key areas, including its pharmacy and wellness segments.
Source: https://finance.yahoo.com/news/cvs-beats-on-earnings-remains-mum-on-2025-revenue-guidance-132927375.html